SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

VOLUNTARY ANNOUNCEMENT
ANNOUNCEMENT ON PHASE I CLINICAL TRIAL OF HECN30227 (siRNA THERAPEUTIC TARGETING HEPATITIS B VIRUS) AND PROGRESS IN THE DEVELOPMENT OF SMALL NUCLEIC ACID PLATFORM

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

REGARDING HECN30227

HECN30227 is a Class 1 new drug independently developed by the Group, for which we hold global intellectual property rights. It simultaneously eliminates hepatitis B surface antigen (HBsAg) originating from both cccDNA and intDNA. Preclinical data indicate that HECN30227 exhibits pan-genotypic activity, which is able to effectively reduce HBsAg levels while maintaining outstanding efficacy against strains that resist nucleoside analogue, with its *in vitro* and *in vivo* efficacy surpassing that of clinical competitors. The employment of HEC-GalNova (N-acetylgalactosamine), a liver-targeting delivery system uniquely designed by the Group, enables HECN30227 to achieve precise and efficient hepatic delivery while substantially reducing off-target risks. Currently, HECN30227 has completed enrolment of the first domestic subject.

The significant findings from the preclinical study of HECN30227 in combination with our proprietary immunomodulator HEC191834 have been selected for the 'Poster of Distinction' at the 2025 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). This distinction is reserved for the top 10% of submissions, signifying the high recognition by a world-renowned academic institution of the clinical development potential of the HECN30227 combination therapy.

REGARDING THE SMALL NUCLEIC ACID TECHNOLOGY PLATFORM

Since 2022, the Group has ventured into the small nucleic acid field, establishing an end-to-end research and development ("**R&D**") platform encompassing'target discovery — sequence design and synthesis — chemical modification — delivery technology — biological evaluation', with Our R&D capabilities ascending to the forefront of the domestic industry. Leveraging this comprehensive technology platform, the Company has filed over 50 patent applications and established more than 10 small nucleic acid pipelines spanning four major therapeutic areas: anti-infectives, cardiovascular-renal-metabolic disorders, respiratory diseases, and oncology. Moving forward, the Company plans to advance multiple small nucleic acid therapeutics into clinical development annually, thereby continuously consolidating its technological leadership in the small nucleic acid therapeutics field.

The key preclinical products include:

1. HBV ASO: In addition to HECN30227, the Company is simultaneously developing a "siRNA + ASO + immunomodulator" combination therapy, which comprehensively suppresses HBV and HBsAg through multi-target synergistic effects. HEC ASO has demonstrated superior preclinical in vitro and in vivo efficacy compared to competitive products.

2. Dual-target series: Through the "one drug, two targets" design, this approach simultaneously silences two pathogenic genes or multiple regions of the same gene, providing an efficient solution for combined interventions in complex diseases. The dual-target pipeline for hyperlipidemia and hyperlipidemia-hypertension is currently showing potent and lasting activity in large animal models. In addition, the dual-target pipeline for indications such as MASH is steadily progressing, and will gradually advance into clinical stages.

3. Fat-targeting, lung-targeting, and antibody-oligonucleotide conjugate (AOC): For the ALK7 target, which is highly expressed in adipose tissue, the Company's proprietary delivery vector has shown significantly superior ALK7 knockdown activity in mouse adipose tissue compared to positive controls, with multiple ALK7 in vitro sequence activities outperforming the positive control. Moreover, the dual-target pipeline for the treatment of pulmonary fibrosis (lung-targeting) and the AOC pipeline for cancer treatment are steadily advancing and will gradually progress into clinical stages in the future.

From the Phase I clinical trial of the HBV siRNA therapy HECN30227 to the rich pipeline of dual-target, fat-targeting, lung-targeting, AOC, and other therapies, the Group is leading the wave of innovation in China's small nucleic acid drugs with a "technology + pipeline + industrialization" multi-dimensional strategy. In the future, the Group will continue to strengthen the development of its small nucleic acid technology platform, step up its effort in addressing unmet clinical needs, and bring the world leading "Smart Made in China" treatment solutions to patients.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
5 January 2026

As at the date of this announcement, the executive directors are Dr. ZHANG Yingjun and Dr. LI Wenjia, the non-executive directors are Mr. ZHANG Yushuai, Mr. TANG Xinfa, Mr. ZHU Yingwei, Mr. ZENG Xuebo, Ms. DONG Xiaowei and Ms. WANG Lei, and the independent non-executive directors are Dr. LI Xintian, Dr. MA Dawei, Dr. YIN Hang Hubert, Dr. LIN Aimei and Dr. YE Tao.